Novartis stakes another PhIII win for Cosentyx, goes deeper into pediatric markets
Just hours after the FDA cleared Novartis’ Cosentyx for its first pediatric indication, the company is following up with more positive data on another: juvenile idiopathic arthritis, or JIA.
The results from the Phase III JUNIPERA study, Novartis says, pave the way for regulatory submissions slated for “the coming weeks,” potentially carving out another big market for the top-selling blockbuster drug that’s facing down rivals from every direction in intensely competitive arenas.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.